Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis.
OBJECTIVE
To evaluate diurnal variation of biomarkers in subjects with osteoarthritis (OA) of the knee.


METHODS
Twenty subjects with radiographic knee OA were admitted to the General Clinical Research Center of Duke University for an overnight stay to undergo serial blood and urine sampling. Biomarkers measured included serum hyaluronan (HA), cartilage oligomeric matrix protein (COMP), keratan sulfate (KS-5D4), aggrecan neoepitope (CS846), high-sensitivity C-reactive protein (hsCRP), osteocalcin, transforming growth factor beta1 (TGFbeta1), and type II collagen (CII)-related epitopes (neoepitope from cleavage of CII [C2C], carboxy-terminus of three-quarter peptide from cleavage of CI and CII [C1,2C], and type II procollagen carboxy-propeptide [CPII] in serum, and C-terminal telopeptides of CII [CTX-II] and C2C in urine).


RESULTS
Levels of serum HA, COMP, KS-5D4, and TGFbeta1 increased significantly from T0 (before arising from bed) to T1 (1 hour after arising). More diurnal variation in HA was observed in patients with higher daily mean HA concentrations. CPII increased significantly from T0 to T2 (4 hours after arising). Urinary concentrations of CTX-II were also found to vary with morning activity, decreasing significantly from T0 to T2. Urinary C2C concentrations increased significantly from T0 until T3 (early evening). No diurnal variations in CS846, hsCRP, osteocalcin, serum C2C, or C1,2C were observed. Six biomarkers (serum C2C, C1,2C, COMP, KS-5D4, TGFbeta1, and urinary CTX-II) were associated with radiographic knee OA (expressed as the sum of Kellgren/Lawrence radiographic severity grades), with the strongest correlations observed with measurements obtained at later time points (either T2 or T3).


CONCLUSIONS
Our study results suggest that serum and urine sampling for HA, COMP, KS-5D4, TGFbeta1, CPII, urinary CTX-II, and urinary C2C should be standardized in future OA clinical trials. Serum and urine sampling at late midday time points may be the optimal approach for OA studies, although this result should be validated in a larger cohort.
Kong
S Y
SY
Duke University Medical Center, Durham, North Carolina 27710, USA.
Stabler
T V
TV
Criscione
L G
LG
Elliott
A L
AL
Jordan
J M
JM
Kraus
V B
VB
D053674:Aggrecans; D015415:Biomarkers / Q000097:blood* / Q000652:urine*; D002097:C-Reactive Protein / Q000032:analysis; D064236:Cartilage Oligomeric Matrix Protein; D011508:Chondroitin Sulfate Proteoglycans / Q000097:blood; D002940:Circadian Rhythm; D024043:Collagen Type II / Q000097:blood / Q000652:urine; D016326:Extracellular Matrix Proteins / Q000097:blood; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D007632:Keratan Sulfate / Q000097:blood; D037181:Lectins, C-Type / Q000097:blood; D064235:Matrilin Proteins; D020370:Osteoarthritis, Knee / Q000097:blood / Q000473:pathology / Q000652:urine; D015675:Osteocalcin / Q000097:blood; D010446:Peptide Fragments / Q000652:urine; D011347:Procollagen / Q000652:urine; D016212:Transforming Growth Factor beta / Q000097:blood; D053773:Transforming Growth Factor beta1
D053674:Aggrecans; D015415:Biomarkers; D064236:Cartilage Oligomeric Matrix Protein; D011508:Chondroitin Sulfate Proteoglycans; D024043:Collagen Type II; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D037181:Lectins, C-Type; D064235:Matrilin Proteins; D010446:Peptide Fragments; D011347:Procollagen; C508960:TGFB1 protein, human; C577553:TSP5 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C093212:procollagen type II carboxy-terminal peptide; D015675:Osteocalcin; D006820:Hyaluronic Acid; D002097:C-Reactive Protein; D007632:Keratan Sulfate